Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends

Reuters

Nov 07

Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends

Overview

Soligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expenses
Company reports no revenue for Q3 2025, same as Q3 2024
Soligenix has $10.5 mln cash, providing runway through 2026

Outlook

Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026
Company plans to carefully allocate resources to achieve strategic goals
Soligenix exploring partnerships and financing to advance late-stage pipeline

Result Drivers

CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial
CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$2.50 mln

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28

Press Release: ID:nPn5tY9PYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581000480"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581000480\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581000480?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581000480","market":"nz","top_or_hot":-1,"title":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Soligenix's Q3 net loss widens on increased R&amp;D spends</title></head><body><p><span>Overview</span></p><ul><li><p>Soligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expenses</p></li><li><p>Company reports no revenue for Q3 2025, same as Q3 2024</p></li><li><p>Soligenix has $10.5 mln cash, providing runway through 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026</p></li><li><p>Company plans to carefully allocate resources to achieve strategic goals</p></li><li><p>Soligenix exploring partnerships and financing to advance late-stage pipeline</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial</p></li><li><p>CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28</p></li></ul><p>Press Release: <span>ID:nPn5tY9PYa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma firm Soligenix's Q3 net loss widens on increased R&D spends\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Soligenix's Q3 net loss widens on increased R&amp;D spends</title></head><body><p><span>Overview</span></p><ul><li><p>Soligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expenses</p></li><li><p>Company reports no revenue for Q3 2025, same as Q3 2024</p></li><li><p>Soligenix has $10.5 mln cash, providing runway through 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026</p></li><li><p>Company plans to carefully allocate resources to achieve strategic goals</p></li><li><p>Soligenix exploring partnerships and financing to advance late-stage pipeline</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial</p></li><li><p>CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28</p></li></ul><p>Press Release: <span>ID:nPn5tY9PYa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ0IB:1","article_id":"2581000480","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581000480","pubTimestamp":1762519253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spendsOverviewSoligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expensesCompany reports no revenue for Q3 2025, sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNGX":"Soligenix, Inc."},"translate_title":"生物制药公司Soligenix第三季度净亏损因研发支出增加而扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spendsOverviewSoligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expensesCompany reports no revenue for Q3 2025, same as Q3 2024Soligenix has $10.5 mln cash, providing runway through 2026OutlookSoligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026Company plans to carefully allocate resources to achieve strategic goalsSoligenix exploring partnerships and financing to advance late-stage pipelineResult DriversCLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trialCASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding optionsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$2.50 mlnAnalyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28Press Release: ID:nPn5tY9PYaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}